Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5464890 | 0.85 | ALDH1A1 (0.42) | HSD17B10LMNAALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL24201945 | 0.83 | HSD17B10 (0.48) | HSD17B10LMNACDC7DBF4ALDH1A1 | |
| SCHEMBL20505660 | 0.81 | HSD17B10 (0.46) | HSD17B10CDC7DBF4ALDH1A1KDM4E | |
| SCHEMBL5255657 | 0.81 | HSD17B10 (0.46) | HSD17B10LMNACDC7DBF4ALDH1A1 | |
| SCHEMBL5458654 | 0.80 | ALDH1A1 (0.41) | LMNAALDH1A1L3MBTL1PRNPCSNK2A2 | |
| SCHEMBL5067504 | 0.79 | ALDH1A1 (0.40) | LMNAALDH1A1KDM4ECSNK2A2CSNK2B | |
| SCHEMBL16012996 | 0.77 | MKNK1 (0.46) | LMNAALDH1A1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL16013302 | 0.75 | MKNK1 (0.52) | LMNAALDH1A1NOTUM | |
| SCHEMBL14031866 | 0.75 | HPGD (0.46) | HSD17B10ALDH1A1KDM4ESMN1; SMN2NOTUM | |
| SCHEMBL5068984 | 0.74 | MKNK2 (0.42) | LMNAALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3939981-B1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LIFEARC (GB) | 2024-04-03 | — | — | EP | disclosed |
| CN-108495855-B | Fused thiazolopyrimidine derivatives as MNK inhibitors | 生命弧度公司 | 2022-05-31 | — | — | CN | disclosed |
| EP-3939981-A1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LifeArc (GB) | 2022-01-19 | — | — | EP | disclosed |
| US-11136338-B2 | Fused thiazolopyrimidine derivatives as MNKs inhibitors | LIFEARC (GB) | 2021-10-05 | — | — | US | disclosed |
| EP-3377501-B1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LIFEARC (GB) | 2021-08-18 | — | — | EP | disclosed |
| US-20200247822-A1 | Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors | ASTRAZENECA UK LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| US-10669284-B2 | Fused thiazolopyrimidine derivatives as MNKS inhibitors | LIFEARC (GB) | 2020-06-02 | — | — | US | disclosed |
| US-20180346483-A1 | Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors | LIFEARC (GB) | 2018-12-06 | — | — | US | disclosed |
| EP-3377501-A1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LifeArc (GB) | 2018-09-26 | — | — | EP | disclosed |
| US-20080269238-A1 | Thiazolopyrimidine Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1731523-A1 | THIAZOLOPYRIMIDINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2006-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346483-A1 | Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors | MAPT, TTBK1, TTBK2 | HSD17B10 1845/4885LMNA 4408/4885CDC7 641/4885 |
| US-20200247822-A1 | Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors | MAPT, TTBK1, TTBK2 | HSD17B10 1740/4885LMNA 4426/4885CDC7 634/4885 |
| US-11136338-B2 | Fused thiazolopyrimidine derivatives as MNKs inhibitors | MAPT, TTBK1, TTBK2 | HSD17B10 1740/4885LMNA 4426/4885CDC7 634/4885 |
| US-20080269238-A1 | Thiazolopyrimidine Derivative | FGFR3, FGFR1, ERBB3 | HSD17B10 1734/4885LMNA 4401/4885CDC7 1529/4885 |
| US-10669284-B2 | Fused thiazolopyrimidine derivatives as MNKS inhibitors | MAPT, TTBK1, TTBK2 | HSD17B10 1845/4885LMNA 4408/4885CDC7 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.